Results 41 to 50 of about 781,343 (307)
Drug Induced Interstitial Lung Disease [PDF]
The Open Respiratory Medicine Journal, 2012 With an increasing number of therapeutic drugs, the list of drugs that is responsible for severe pulmonary disease also grows. Many drugs have been associated with pulmonary complications of various types, including interstitial inflammation and fibrosis, bronchospasm, pulmonary edema, and pleural effusions. Drug-induced interstitial lung disease (DILD)
Schwaiblmair, Martin +5 more
openaire +3 more sources
Idiopathic pleuroparenchymal fibroelastosis (PPFE) – A case study of a rare entity
Revista Portuguesa de Pneumologia (English Edition), 2017 Idiopathic pleuroparenchymal fibroelastosis (IPPFE) was recognized as a rare new entity. We report the case of a 63 years old female suffering from progressive dyspnea and dry cough for three years.
E.B. Boerner +4 more
doaj +1 more source
Prognostic factors in chronic hypersensitivity pneumonitis
European Respiratory Review, 2020 Hypersensitivity pneumonitis (HP) is an immunologically mediated lung disease resulting from exposure to inhaled environmental antigens. Prognosis is variable, with a subset of patients developing progressive fibrosis leading to respiratory failure and ...
Andrew W. Creamer, Shaney L. Barratt
doaj +1 more source
Immune mechanisms in fibrotic pulmonary sarcoidosis
European Respiratory Review, 2022 Sarcoidosis is an immune-mediated disorder. Its immunopathology has been steadily mapped out over the past few decades. Despite this, the underpinning mechanisms for progressive fibrotic sarcoidosis is an almost uncharted area.
Praveen Weeratunga +2 more
doaj +1 more source
Rituximab‐induced interstitial lung disease [PDF]
American Journal of Hematology, 2005 AbstractThe aim of this study is to characterize rituximab‐induced interstitial lung disease (R‐ILD). The information on all reported cases of R‐ILD was reviewed. This analysis focused on patient characteristics, underlying disease, rituximab dosing schedule, and R‐ILD characteristic‐like symptoms, diagnosis, treatment, and outcomes. Sixteen cases of R‐
Stephanie A, Wagner +2 more
openaire +2 more sources
BMC Pulmonary Medicine, 2019 Background Diffuse alveolar haemorrhage (DAH) is characterized by the diffuse accumulation of red blood cells within the alveoli, presence of ground glass opacities and/or consolidation on computed tomography (CT).
Anna Stainer +9 more
doaj +1 more source
Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
Frontiers in Medicine, 2020 After decades of research, two therapies for chronic fibrotic lung disease are now approved by the FDA, with dozens more anti-fibrotic therapies in the pipeline.
Sachin Chaudhary +5 more
doaj +1 more source
Assessment of pulmonary edema: principles and practice [PDF]
, 2018 Pulmonary edema increasingly is recognized as a perioperative complication affecting outcome. Several risk factors have been identified, including those of cardiogenic origin, such as heart failure or excessive fluid administration, and those related to ...
Assaad, Sherif +4 more
core +1 more source
Quantitative CT analysis in patients with pulmonary emphysema: is lung function influenced by concomitant unspecific pulmonary fibrosis? [PDF]
, 2019 Purpose: Quantitative analysis of CT scans has proven to be a reproducible technique, which might help to understand the pathophysiology of chronic obstructive pulmonary disease (COPD) and combined pulmonary fibrosis and emphysema.
Doellinger, Felix +5 more
core +1 more source
Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)
European Respiratory Journal, 2020 In patients with chronic fibrosing interstitial lung disease (ILD), a progressive fibrosing phenotype (PF-ILD) may develop, but information on the frequency and characteristics of this population outside clinical trials is lacking.
M. Nasser +14 more
semanticscholar +1 more source